T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses In Vivo

被引:8
|
作者
Klein, Klara [1 ]
Witalisz-Siepracka, Agnieszka [1 ,2 ]
Gotthardt, Dagmar [1 ]
Agerer, Benedikt [3 ]
Locker, Felix [4 ]
Grausenburger, Reinhard [1 ]
Knab, Vanessa Maria [1 ]
Bergthaler, Andreas [3 ]
Sexl, Veronika [1 ]
机构
[1] Univ Vet Med Vienna, Inst Pharmacol & Toxicol, Vienna, Austria
[2] Karl Landsteiner Univ Hlth Sci, Div Pharmacol, Dept Pharmacol Physiol & Microbiol, Krems, Austria
[3] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria
[4] Univ Vet Med, Inst Physiol Pathophysiol & Biophys, Vienna, Austria
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
基金
欧洲研究理事会; 奥地利科学基金会;
关键词
CDK6; CD8+T cells; metabolism; interferon signaling; suppressor of cytokine signaling (SOCS); anti-viral response; anti-tumor response; CLONAL EXPANSION; IMMUNE-RESPONSE; KINASE-ACTIVITY; SOCS PROTEINS; CUTTING EDGE; CDK4/6; INHIBITION; SUPPRESSOR; RECEPTOR; PALBOCICLIB;
D O I
10.3389/fimmu.2021.650977
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The cyclin-dependent kinase 6 (CDK6) regulates the transition through the G1-phase of the cell cycle, but also acts as a transcriptional regulator. As such CDK6 regulates cell survival or cytokine secretion together with STATs, AP-1 or NF-kappa B. In the hematopoietic system, CDK6 regulates T cell development and promotes leukemia and lymphoma. CDK4/6 kinase inhibitors are FDA approved for treatment of breast cancer patients and have been reported to enhance T cell-mediated anti-tumor immunity. The involvement of CDK6 in T cell functions remains enigmatic. We here investigated the role of CDK6 in CD8+ T cells, using previously generated CDK6 knockout (Cdk6 (-/-)) and kinase-dead mutant CDK6 (Cdk6 (K43M)) knock-in mice. RNA-seq analysis indicated a role of CDK6 in T cell metabolism and interferon (IFN) signaling. To investigate whether these CDK6 functions are T cell-intrinsic, we generated a T cell-specific CDK6 knockout mouse model (Cdk6 (fl/fl) CD4-Cre). T cell-intrinsic loss of CDK6 enhanced mitochondrial respiration in CD8+ T cells, but did not impact on cytotoxicity and production of the effector cytokines IFN-gamma and TNF-alpha by CD8+ T cells in vitro. Loss of CDK6 in peripheral T cells did not affect tumor surveillance of MC38 tumors in vivo. Similarly, while we observed an impaired induction of early responses to type I IFN in CDK6-deficient CD8+ T cells, we failed to observe any differences in the response to LCMV infection upon T cell-intrinsic loss of CDK6 in vivo. This apparent contradiction might at least partially be explained by the reduced expression of Socs1, a negative regulator of IFN signaling, in CDK6-deficient CD8+ T cells. Therefore, our data are in line with a dual role of CDK6 in IFN signaling; while CDK6 promotes early IFN responses, it is also involved in the induction of a negative feedback loop. These data assign CDK6 a role in the fine-tuning of cytokine responses.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Autophagy Regulation of Metabolism Is Required for CD8+ T Cell Anti-tumor Immunity
    DeVorkin, Lindsay
    Pavey, Nils
    Carleton, Gillian
    Comber, Alexandra
    Ho, Cally
    Lim, Junghyun
    McNamara, Erin
    Huang, Haochu
    Kim, Paul
    Zacharias, Lauren G.
    Mizushima, Noboru
    Saitoh, Tatsuya
    Akira, Shizuo
    Beckham, Wayne
    Lorzadeh, Alireza
    Moksa, Michelle
    Cao, Qi
    Murthy, Aditya
    Hirst, Martin
    DeBerardinis, Ralph J.
    Lum, Julian J.
    CELL REPORTS, 2019, 27 (02): : 502 - +
  • [32] Tumor Cell-associated Exosomes Robustly Elicit Anti-tumor Immune Responses through Modulating Dendritic Cell Vaccines in Lung Tumor
    Wang, Ce
    Huang, Xue
    Wu, Yingjuan
    Wang, Jingbo
    Li, Furong
    Guo, Guoqing
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2020, 16 (04): : 633 - 643
  • [33] How does TCR-T cell therapy exhibit a superior anti-tumor efficacy
    Yang, Dandan
    Duan, Zhihui
    Yuan, Ping
    Ding, Chengming
    Dai, Xiaoming
    Chen, Guodong
    Wu, Daichao
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 687
  • [34] Group 2 innate lymphoid cells boost CD8+ T-cell activation in anti-tumor immune responses
    Wen, Jing
    Cheng, Shipeng
    Wang, Ran
    Huang, Yuying
    Xu, Long
    Ma, Liyan
    Ling, Zhiyang
    Xu, Jinfu
    Zhao, Deping
    Zhang, Yaguang
    Sun, Bing
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [35] Apolipoprotein E deficiency enhances the anti-tumor immunity via repressing T cell exhaustion
    Zhao, Bian
    Wang, Wenbao
    Chen, Zhijun
    Jin, Shaoju
    ALL LIFE, 2021, 14 (01) : 1054 - 1062
  • [36] CDK4/6 nano-PROTAC enhances mitochondria-dependent photodynamic therapy and anti-tumor immunity
    Wang, Tianyi
    Zhang, Yaming
    Chen, Kang
    Huang, Yi
    Liu, Yuwei
    Xu, Shuting
    Wang, Weiping
    NANO TODAY, 2023, 50
  • [37] CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (vol 12, 942341, 2022)
    Digiacomo, Graziana
    Fumarola, Claudia
    La Monica, Silvia
    Bonelli, Mara
    Cavazzoni, Andrea
    Galetti, Maricla
    Terenziani, Rita
    Eltayeb, Kamal
    Volta, Francesco
    Zoppi, Silvia
    Bertolini, Patrizia
    Missale, Gabriele
    Alfieri, Roberta
    Petronini, Pier Giorgio
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [38] Cell-Intrinsic Transforming Growth Factor-β Signaling Mediates Virus-Specific CD8+ T Cell Deletion and Viral Persistence In Vivo
    Tinoco, Roberto
    Alcalde, Victor
    Yang, Yating
    Sauer, Karsten
    Zuniga, Elina I.
    IMMUNITY, 2009, 31 (01) : 145 - 157
  • [39] Anti-invasion and anti-tumor growth effect of doxycycline treatment for human oral squamous-cell carcinoma - In vitro and in vivo studies
    Shen, Ling-Chang
    Chen, Yuk-Kwan
    Lin, Li-Min
    Shaw, Shyh-Yu
    ORAL ONCOLOGY, 2010, 46 (03) : 178 - 184
  • [40] Dominant negative TGF-β receptor type II in T lymphocytes promotes anti-tumor immunity by modulating T cell subsets and enhancing CTL responses
    Li, Hao
    Guan, Yanling
    Han, Chenchen
    Zhang, Yu
    Chen, Yizhao
    Jiang, Liping
    Zhang, Pingping
    Chen, Xiu
    Wei, Wei
    Ma, Yang
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 148